OZEMPIC
PeakNDASUBCUTANEOUSSOLUTION
Approved
Dec 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
6
Data completeness
5/8 — Partial
Drug Shortage Active
OZEMPIC is currently in shortage. Reason: Demand increase. This may impact manufacturing, supply chain, and quality hiring at the manufacturer.
OZEMPIC by Novo Nordisk is glp-1 analogue with 94% sequence homology to human glp-1. First approved in 2017.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OZEMPIC (semaglutide) is a GLP-1 receptor agonist approved in December 2017 for type 2 diabetes management. It works by stimulating insulin secretion and inhibiting glucagon in a glucose-dependent manner, with a long half-life enabled by albumin binding and DPP-4 stabilization. The drug also delays gastric emptying to help reduce postprandial glucose excursions.
$9.2BPart D
PeakGrowing
14.4 years to LOEAt peak lifecycle with $9.2B in Part D spending, OZEMPIC commands significant commercial resources and team expansion across sales, marketing, and medical affairs functions.
Mechanism of Action
GLP-1 analogue with 94% sequence homology to human GLP-1. Semaglutide acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1. GLP-1 is a physiological hormone that has multiple actions on glucose, mediated by the GLP-1 receptors. The…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (6)
A Two-armed Real-world Study of Ozempic (OW Semaglutide) to Evaluate Its Adherence and Persistence Compared With Other Anti-diabetic Drugs Among Adult T2DM Patients in China
Started Feb 2026
100,000 enrolled
Type 2 Diabetes
Regulatory Post Marketing Surveillance (rPMS) Study of Ozempic (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea
Started Feb 2026
600 enrolled
Diabetes Mellitus, Type 2
A Research Study to Understand How People With Type 2 Diabetes Take Ozempic® and if the Ozempic®App Helps Them Stay on This Treatment
Started Jun 2024
304 enrolled
Diabetes Mellitus, Type 2
Real-world Study of CHina Ozempic cLinicAl pRactice in Patients With Type 2 Diabetes (SCHOLAR)
Started Jan 2024
34,238 enrolled
Diabetes Mellitus, Type 2
Open Randomized Study of Comparative Pharmacokinetics and Biosimilarity of GP40221 (GEROPHARM LLC, Russia) and Ozempic®.
Started Jun 2023
120 enrolled
PharmacokineticsSafety IssuesBioequivalence
Worked on OZEMPIC at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.